Mutations of the common gamma chain (γc) of cytokine receptors cause X-linked severe combined immunodeficiency (XSCID), a candidate disease for gene therapy. Using an XSCID murine model, we have tested the feasibility of stem cell gene correction. XSCID bone marrow (BM) cells were transduced with a retroviral vector expressing the murine γc (mγc) and engrafted in irradiated XSCID animals. Transplanted mice developed mature B cells, naıve T cells, and mature natural killer (NK) cells, all of which were virtually absent in untreated mice. The mγc transgene was detected in all treated mice, and we could demonstrate mγc expression in newly developed lymphocytes at both the RNA and protein level. In addition, treated mice showed T cell proliferation responses to mitogens and production of antigen-specific antibodies upon immunization. Four of seven treated animals showed a clear increase of the transgene positive cells, suggesting in vivo selective advantage for gene-corrected cells. Altogether, these results show that retroviral-mediated gene transfer can improve murine XSCID and suggest that similar strategies may prove beneficial in human clinical trials.